US 12,344,657 B2
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
Hans Bitter, Lincoln, MA (US); Jennifer Mary Bordeaux, Carlsbad, CA (US); Barbara Brannetti, Cambridge, MA (US); Jennifer Brogdon, Sudbury, MA (US); Naveen Kumar Dakappagari, Carlsbad, CA (US); Saar Gill, Philadelphia, PA (US); Steven Highfill, Bethesda, MD (US); Lu Huang, West Roxbury, MA (US); Carl H. June, Merion Station, PA (US); Ju Young Kim, Carlsbad, CA (US); Ming Lei, Acton, MA (US); Na Li, Cambridge, MA (US); Andreas Loew, Boston, MA (US); Elena Orlando, Somerville, MA (US); Marco Ruella, Ardmore, PA (US); Thai Tran, Carlsbad, CA (US); Jimin Zhang, Chestnut Hill, MA (US); and Li Zhou, Cambridge, MA (US)
Assigned to Novartis AG, Basel (CH); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by Novartis AG, Basel (CH); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed on Sep. 1, 2021, as Appl. No. 17/464,528.
Application 17/464,528 is a division of application No. 16/256,731, filed on Jan. 24, 2019, granted, now 11,149,076.
Application 16/256,731 is a division of application No. 15/094,674, filed on Apr. 8, 2016, granted, now 10,253,086, issued on Apr. 9, 2019.
Claims priority of provisional application 62/263,423, filed on Dec. 4, 2015.
Claims priority of provisional application 62/207,255, filed on Aug. 19, 2015.
Claims priority of provisional application 62/144,615, filed on Apr. 8, 2015.
Claims priority of provisional application 62/144,639, filed on Apr. 8, 2015.
Claims priority of provisional application 62/144,497, filed on Apr. 8, 2015.
Prior Publication US 2022/0195010 A1, Jun. 23, 2022
Int. Cl. C07K 14/705 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/36 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 14/70596 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/36 (2025.01); A61K 40/4211 (2025.01); A61K 40/4212 (2025.01); A61K 40/4217 (2025.01); A61K 40/4221 (2025.01); A61K 45/06 (2013.01); C07K 14/7051 (2013.01); C07K 16/2803 (2013.01); C07K 16/2866 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); A61K 38/00 (2013.01); A61K 2039/70 (2013.01); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01)] 27 Claims
 
1. A method of treating a young adult or pediatric subject having a cancer comprising administering to the subject an effective amount of a population of cells that comprises a CAR molecule comprising a CD19 binding domain and a CD22 binding domain, wherein:
(i) the CD19 binding domain comprises a scFv comprising the LC CDR1, LC CDR2, LC CDR3, HC CDR1, HC CDR2, and HC CDR3 of FMC63; and
(ii) the CD22 binding domain comprises a scFv comprising the LC CDR1, LC CDR2, LC CDR3, HC CDR1, HC CDR2, and HC CDR3 of m971,
wherein the population of cells that comprises a CAR molecule is administered at a dose of 104 cells/kg to 2×107 cells/kg.